Caspofungin for Pneumocystis Pneumonia in HIV patients
Part of Infections, Lungs & breathing clinical trials.
This trial tests caspofungin, a medicine, for treating Pneumocystis pneumonia (PCP) in people living with HIV. It aims to see if it works better than standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Pneumocystis pneumonia (PCP) that is either proven or probable based on specific medical criteria.
- You must have had lab tests (both clinical and virological) done when you were admitted to the hospital.
- You cannot have had your treatment changed to caspofungin after 7 days of starting therapy (this only applies if you are in group B).
- You must not have developed another lung infection during your hospital stay, except for certain infections like cytomegalovirus or COVID-19.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new inhaled medicine (caspofungin) added to standard treatment for Pneumocystis pneumonia, a serious lung infection. It may help fight the infection more effectively while you are already receiving oxygen and standard antibiotics.
This Phase 2 trial tests rezafungin, an antifungal medicine, to treat Pneumocystis pneumonia (PCP) in adults living with HIV. It may help people recover faster or more effectively from this serious lung infection.
This Phase 3 study tests whether low-dose trimethoprim-sulfamethoxazole (also called TMP-SMX) can treat Pneumocystis pneumonia (PCP) in people with weakened immune systems. It may help improve treatment while reducing side effects compared with standard dosing.
This study tests whether short-term steroid treatment helps adults with a specific lung infection (PCP) that happens with HIV/AIDS. It compares outcomes in people who start steroids soon after admission while also taking standard PCP antibiotics.
This study compares different second-line antibiotics for treating Pneumocystis pneumonia (a serious lung infection) in people with weakened immune systems. It aims to find the best alternative when the standard treatment cannot be used.
This trial tests a new way to diagnose pneumocystis, a lung infection that can affect people with weakened immune systems. It may help find the infection faster and more accurately using samples taken from your lungs.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.